Enzyme Replacement in Murine Mucopolysaccharidosis Type VII: Neuronal and Glial Response to β-Glucuronidase Requires Early Initiation of Enzyme Replacement Therapy

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Pediatric Research

• Publication date

  1999-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1203/00006450-199906000-00010PMID 10367775
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function.

  1998cited by this paper
• Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

  1997cited by this paper
• Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation.

  1997cited by this paper
• Uptake of α-(L)-iduronidase produced by retrovirally transduced fibroblasts into neuronal and glial cells in vitro

  1997cited by this paper
• 8 Enzyme replacement therapy for Gaucher's disease

  1997cited by this paper
• Neuropathology of murine mucopolysaccharidosis type VII

  1996cited by this paper
• Enzyme Replacement with Recombinant β-Glucuronidase in Murine Mucopolysaccharidosis Type VII: Impact of Therapy during the First Six Weeks of Life on Subsequent Lysosomal Storage, Growth, and Survival

  1996cited by this paper
• Myoblast Gene Therapy in Canine Mucopolysaccharidosis I: Abrogation by an Immune Response to α-l-Iduronidase

  1996cited by this paper
• Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

  1996cited by this paper
• Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation

  1995cited by this paper
• Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources

  1995cited by this paper
• Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease.

  1994cited by this paper
• Pathology of the ear in murine mucopolysaccharidosis type VII. Morphologic correlates of hearing loss.

  1994cited by this paper
• Enzyme replacement therapy for murine mucopolysaccharidosis type VII.

  1994cited by this paper
• Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment.

  1994cited by this paper
• Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates.

  1993cited by this paper
• Behavioural abnormalities in a murine model of a human lysosomal storage disease.

  1993cited by this paper
• Enzyme Replacement with Recombinant β-Glucuronidase in the Newborn Mucopolysaccharidosis Type VII Mouse

  1993cited by this paper
• Long-term outcome of Hurler syndrome following bone marrow transplantation.

  1993cited by this paper
• Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer

  1992cited by this paper
• Amelioration of clinical disease following bone marrow transplantation in fucosidase-deficient dogs.

  1992cited by this paper
• Hepatic Storage of Glycosaminoglycans in Feline and Canine Models of Mucopolysaccharidoses I, VI, and VII

  1992cited by this paper
• Expression of the two mannose 6-phosphate receptors is spatially and temporally different during mouse embryogenesis.

  1992cited by this paper
• Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

  1991cited by this paper
• Enzyme replacement therapy for Gaucher disease.

  1991cited by this paper
• Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation.

  1991cited by this paper
• Expression of the IGF-II/mannose-6-phosphate receptor mRNA and protein in the developing rat.

  1990cited by this paper
• A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice.

  1990cited by this paper
• Developmental expression of the tissue insulin-like growth factor II/mannose 6-phosphate receptor in the rat. Measurement by quantitative immunoblotting.

  1989cited by this paper
• Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency.

  1989cited by this paper
• Long-Term Neurological Effects of Bone Marrow Transplantation in a Canine Lysosomal Storage Disease

  1988cited by this paper
• Interendothelial junctional changes underlie the developmental 'tightening' of the blood-brain barrier.

  1987cited by this paper
• Beta-glucuronidase deficiency mucopolysaccharidosis: methods for enzymatic diagnosis.

  1973cited by this paper
• Beta-glucuronidase deficiency mucopolysaccharidosis: methods for enzymatic diagnosis.

  1973cited by this paper
• Clinical Chemistry 43:8 1325–1335 (1997) Molecular Pathology

  year unknowncited by this paper

• Strategies for blood-brain barrier rejuvenation and repair.

  2026cites this paper
• Clinical Case of Drug Allergy to Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II

  2022cites this paper
• Mucopolysaccharidoses and the blood–brain barrier

  2022cites this paper
• Do cytokines play role in the pathogenesis of mucopolysaccharidosis

  2021cites this paper
• Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.

  2020cites this paper
• Tolerance induction and microglial engraftment after fetal therapy without conditioning in mice with mucopolysaccharidosis type VII

  2020cites this paper
• Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice

  2017cites this paper
• Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II

  2017cites this paper
• Pharmacologic manipulation of lysosomal enzyme transport across the blood–brain barrier

  2016cites this paper
• From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery

  2016cites this paper
• Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

  2016cites this paper
• Chronic enzyme replacement therapy ameliorates neuropathology in alpha‐mannosidosis mice

  2015cites this paper
• Prospective therapies for mucopolysaccharidoses

  2015cites this paper
• Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies.

  2014cites this paper
• Intrathecal delivery of protein therapeutics to the brain: a critical reassessment.

  2014cites this paper
• High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector

  2014cites this paper
• Therapeutic approaches to Lysosomal Storage Disorders: the example of Pompe Disease

  2014cites this paper
• Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.

  2013cites this paper
• Therapies for Lysosomal Storage Diseases

  2013cites this paper
• Human β-Glucuronidase: Structure, Function, and Application in Enzyme Replacement Therapy

  2013cites this paper
• Toward the successful delivery of lysosomal enzymes across the blood–brain barrier

  2013cites this paper
• Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age.

  2012cites this paper
• Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.

  2012cites this paper
• Lysosomal Storage, Peroxisomal, and Glycosylation Disorders and Smith–Lemli–Opitz Syndrome Presenting in the Neonate

  2012cites this paper
• Systemic Administration of Tripeptidyl Peptidase I in a Mouse Model of Late Infantile Neuronal Ceroid Lipofuscinosis: Effect of Glycan Modification

  2012cites this paper
• Large proteoglycan complexes and disturbed collagen architecture in the corneal extracellular matrix of mucopolysaccharidosis type VII (Sly syndrome).

  2011cites this paper
• New Strategies for Enzyme Replacement Therapy for Lysosomal Storage Diseases

  2010cites this paper
• Mouse models of neurological disorders: a view from the blood-brain barrier.

  2010cites this paper
• Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.

  2010cites this paper
• Replacing the Enzyme α-l-Iduronidase at Birth Ameliorates Symptoms in the Brain and Periphery of Dogs with Mucopolysaccharidosis Type I

  2010cites this paper
• Characteristics of compounds that cross the blood-brain barrier

  2009cites this paper
• Involvement of the Toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidoses

  2009cites this paper
• Examination of intravenous and intra‐CSF protein delivery for treatment of neurological disease

  2009cites this paper
• Enzyme replacement therapy treatment from birth increases therapeutic effic acy and generates tolerance to enzyme in canine mucopolysaccharidosis type I

  2009cites this paper
• Lysosomal storage diseases and the blood-brain barrier.

  2008cites this paper
• 4Blood Brain Barrier

  2008cites this paper
• Central nervous system therapy for lysosomal storage disorders.

  2008cites this paper
• Les maladies génétiques du chat domestique

  2008cites this paper
• Treatment of lysosomal storage disorders: focus on the neuronal ceroid-lipofuscinoses.

  2008cites this paper
• Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.

  2008cites this paper
• The blood-brain barrier: connecting the gut and the brain.

  2008cites this paper
• Caprine mucopolysaccharidosis IIID

  2007influential citation
• Clinical response to persistent, low-level β-glucuronidase expression in the murine model of mucopolysaccharidosis type VII

  2007cites this paper
• Bone marrow fails to differentiate into liver epithelium during murine development and regeneration

  2007cites this paper
• Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation

  2007cites this paper
• Enzyme replacement therapy in a murine model of Morquio A syndrome.

  2007cites this paper
• Animal models for mucopolysaccharidosis disorders and their clinical relevance

  2007cites this paper
• Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase.

  2007cites this paper
• Caprine mucopolysaccharidosis IIID

  2007cites this paper
• Epinephrine enhances lysosomal enzyme delivery across the blood–brain barrier by up-regulation of the mannose 6-phosphate receptor

  2007cites this paper
• Reversibility of cellular and organ pathology in enzyme replacement trials in animal models of lysosomal storage diseases.

  2006cites this paper
• Encapsulation cell therapy for mucopolysaccharidosis type VII using genetically engineered immortalized human amniotic epithelial cells.

  2006cites this paper
• Enzyme replacement therapy in alpha-mannosidosis guinea-pigs.

  2006cites this paper
• Enzyme replacement therapy in a-mannosidosis guinea-pigs

  2006cites this paper
• Reversibility of cellular and organ pathology in enzyme replacement trials in animal models of lysosomal storage diseases

  2006cites this paper
• to human and mouse β-glucuronidase

  2006cites this paper
• Therapy of Lysosomal Storage Diseases

  2005cites this paper
• Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase.

  2005cites this paper
• Early Onset of Lysosomal Storage Disease in a Murine Model of Mucopolysaccharidosis Type VII: Undegraded Substrate Accumulates in Many Tissues in the Fetus and Very Young MPS VII Mouse

  2005cites this paper
• A breach in the blood-brain barrier.

  2005cites this paper
• 15 N-Glycan Engineering in Yeasts and Fungi: Progress toward Human-Like Glycosylation

  2005cites this paper
• Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.

  2005cites this paper
• Extracellular β-Glucuronidase for Gene-Directed Enzyme-Prodrug Therapy

  2004cites this paper
• Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study.

  2004cites this paper
• Enzyme replacement and enhancement therapies for lysosomal diseases

  2004cites this paper
• Expression of lysosomal protective protein/cathepsin A in a stably transformed human neuroblastoma cell line during bi-directional differentiation into neuronal and Schwannian cells.

  2004cites this paper
• Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier.

  2004cites this paper
• In vitro characterization of genetically modified embryonic stem cells as a therapy for murine mucopolysaccharidosis type IIIA.

  2004cites this paper
• Encapsulated, genetically modified cells producing in vivo therapeutics.

  2004cites this paper
• Electrocardiographic and other cardiac anomalies in beta-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation.

  2004cites this paper
• Specific Treatment for Lysosomal Storage Disorders: Enzyme Replacement Therapy, Bone Marrow Transplant and Others

  2004cites this paper
• Gene therapy for lysosomal storage diseases: the lessons and promise of animal models

  2004cites this paper
• Improvement of skeletal lesions in mice with mucopolysaccharidosis type VII by neonatal adenoviral gene transfer.

  2003cites this paper
• human and mouse b-glucuronidase

  2003cites this paper
• Donor cell replacement in mice transplanted in utero is limited by immune-independent mechanisms.

  2003cites this paper
• Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII

  2003cites this paper
• Gene therapy for mucopolysaccharidosis.

  2003cites this paper
• Gene Transfer Strategies for Correction of Lysosomal Storage Disorders

  2003cites this paper
• Gene therapy for mucopolysaccharidosis.

  2003cites this paper
• Donor cell expansion is delayed following nonablative in utero transplantation to treat murine mucopolysaccharidosis type VII.

  2003cites this paper
• Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer

  2003cites this paper
• Production of MPS VII mouse (Gustm(hE540A.mE536A)Sly) doubly tolerant to human and mouse β-glucuronidase

  2003cites this paper
• Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase.

  2003cites this paper
• Brain-directed gene therapy for lysosomal storage disease: Going well beyond the blood– brain barrier

  2002cites this paper
• Animal models for mucopolysaccharidoses and their clinical relevance

  2002cites this paper
• Enzyme replacement therapy for the mucopolysaccharide storage disorders

  2002cites this paper
• Urinary glycosaminoglycan excretion quantified by an automated semimicro method in specimens conveniently transported from around the globe.

  2002cites this paper
• Enzyme replacement and enhancement therapies: lessons from lysosomal disorders

  2002cites this paper
• 3 Positional candidate gene cloning of CLN1

  2001cites this paper
• Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII.

  2001cites this paper
• Mucopolysaccharidosis type VII (Sly syndrome) presenting as neonatal cholestasis with hepatosplenomegaly.

  2001cites this paper
• Biodistribution, Kinetics, and Efficacy of Highly Phosphorylated and Non-phosphorylated β-Glucuronidase in the Murine Model of Mucopolysaccharidosis VII*

  2001cites this paper
• Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer

  2001cites this paper
• Murine mucopolysaccharidosis VIL: impact of therapies on the phenotype, clinical course, and pathology in a model of a lysosomal storage disease.

  2001cites this paper
• Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency.

  2001cites this paper
• Active site mutant transgene confers tolerance to human β-glucuronidase without affecting the phenotype of MPS VII mice

  2001cites this paper
• Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII.

  2001cites this paper
• In utero fetal liver cell transplantation without toxic irradiation alleviates lysosomal storage in mice with mucopolysaccharidosis type VII.

  2001cites this paper
• Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function.

  2000cites this paper
• Short-term enzyme replacement in the murine model of Sanfilippo syndrome type B.

  2000cites this paper